January 13, 2021 -- Cytovia Therapeutics has signed a licensing agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to apply its gene-edited induced pluripotent stem cell (iPSC)-derived technology to develop glypican-3 (GPC3) chimeric antigen receptor (CAR) natural killer (NK) cell therapeutics.
Mitchell Ho, PhD, director of the Antibody Engineering Program and deputy chief of the Laboratory of Molecular Biology at the NCI Center for Cancer Research has developed novel antibodies and CARs binding to GPC3 on liver cancer cells. GPC3 is an antigen involved in cell proliferation and is highly expressed in hepatocellular carcinoma tumor cells as well as other solid tumors.
Cytovia has also signed a cooperative research and development agreement with NCI where the company will collaborate with the Ho lab to develop and evaluate gene-edited iPSC-derived CAR NK cells. The company plans to file an initial new drug application for its GPC3 CAR NK cells in the first half of 2022.